ArticleJournal of cardiothoracic surgery2026
Unveiling CTGF and APOA1: key hub genes and therapeutic targets in dilated cardiomyopathy.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDilated cardiomyopathy (DCM), a life-threatening cardiovascular disease, affects more than 0.04% of the general population. However, the key genes associated with DCM are still unknown.
methodsThree publicly available datasets (GSE120895, GSE53081, and GSE42955) were obtained from the Gene Expression Omnibus (GEO) database. Weighted correlation network analysis (WGCNA), gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on these DEGs. A protein‒protein interaction (PPI) network was then constructed to select the hub genes.
results862 differentially expressed genes (DEGs) were identified using an integrated bioinformatics approach. WGCNA indicated that DEGs in the blue and turquoise modules exhibited the strongest associations with DCM risk (blue module: r = 0.29, P = 2.5e-4; turquoise module: r = 0.25, P = 1.6e-3). KEGG pathway enrichment analysis of the hub genes revealed that the RTK-RAS pathway score was associated with DCM risk. Receiver operating characteristic (ROC) analysis revealed that the expression levels of CTGF and APOA1 may serve as sensitive and specific predictors of DCM risk (AUC of CTGF = 0.83, P = 0.002; AUC of APOA1 = 0.867, P = 0.001). Furthermore, the expression of CTGF and APOA1 was confirmed by Western blot.
conclusionsOur results revealed that CTGF and APOA1 are correlated with DCM risk and represent potential biomarkers worthy of further investigation. The identification of these hub genes and the implicated RTK-RAS pathway provides a hypothesis and a direction for future functional research on DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.